100/50/4 mg/ml spot-on, 2 ml for dogs over 10-20 kg
Assessed clinical scopeDog · Full labelled canine topical scope in the exact weight band: fleas, lice, biting lice and ixodid ticks; gastrointestinal nematodes and cestodes; heartworm-larval prevention · On the skin
Care settingVeterinary-selected home application to dry intact skin after parasite-risk and heartworm assessment, with diagnostic follow-up for established infection
vetman score
4.7/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, veterinary · № 000920 · Verified on 21 Oct 2026
The exact product is identifiable and locally registered, but its unusually broad topical claims are supported mainly by the current instruction and indirect, old or formulation-mismatched evidence. Prefer better-documented parasite-specific options when available; if selected, use the exact weight band with explicit heartworm assessment and follow-up.
Regulatory and scientific credibility4.0/10
The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.
Clinical efficacy4.0/10
Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.
Safety and tolerability4.5/10
The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.
Clinical practicality7.5/10
A whole weight-banded pipette makes dose selection straightforward and administration is a single topical event. Correct skin placement, prevention of licking, 48 hours without washing or close human contact and different general-parasite versus heartworm intervals add meaningful treatment burden.
Full-course cost-effectiveness-
Price was not assessed and is excluded from the overall score.
Important safety and use flags
- Do not use with known hypersensitivity, in animals below 2 months of age, in infectious disease or debilitation, or on wet or damaged skin.
- Do not use concurrently with another antiparasitic because toxicity may be potentiated. Interaction information for other medicine classes is unavailable.
- The instruction does not recommend use in Collies, Shelties or Bobtails because of avermectin sensitivity; resolve ABCB1 risk before considering use in any susceptible dog.
- Prevent licking and observe until dry. Local erythema or pruritus may occur; overdose or oral exposure can cause depression, hypersalivation and vomiting—wash the product off and assess clinically.
- During pregnancy or lactation, use only under veterinary supervision after an individual benefit-risk assessment; robust reproductive safety data for the exact combination were not found.
- This is prevention against susceptible Dirofilaria larval stages, not treatment of adult heartworm disease. Assess exposure and infection status before prophylaxis and follow current heartworm guidance.
- Apply the exact whole-pipette dose directly to dry intact skin where it cannot be licked. Do not wash with detergent for 48 hours; avoid stroking and contact with small children for 48 hours.
Assessment sources+
